Patents by Inventor Norbert Kienzle

Norbert Kienzle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Humanized antibodies with anti-tumor activity
    Patent number: 8901279
    Abstract: The present invention provides humanised antibodies and binding domains thereof with anti-tumor activity. In particular the humanised antibodies have specific binding to and direct killing of human colon tumor cells and display potent immune-mediated cytotoxic activity against human colon cancer cells in vitro using antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) assays and in vivo using mouse tumor models.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: December 2, 2014
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: Adam W. Clarke, Anthony G. Doyle, Philip A. Jennings, Norbert Kienzle, Matthew Pollard
  • Humanized Antibodies with Anti-Tumor Activity
    Publication number: 20130280246
    Abstract: The present invention provides humanised antibodies and binding domains thereof with anti-tumour activity. In particular the humanised antibodies have specific binding to and direct killing of human colon tumour cells and display potent immune-mediated cytotoxic activity against human colon cancer cells in vitro using antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) assays and in vivo using mouse tumour models.
    Type: Application
    Filed: May 21, 2013
    Publication date: October 24, 2013
    Inventors: Adam W. Clarke, Anthony G. Doyle, Philip A. Jennings, Norbert Kienzle, Matthew Pollard
  • Humanised antibodies with anti-tumour activity
    Patent number: 8470320
    Abstract: The present invention provides humanized antibodies and binding domains thereof with anti-tumor activity. In particular the humanized antibodies have specific binding to and direct killing of human colon tumor cells and display potent immune-mediated cytotoxic activity against human colon cancer cells in vitro using antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) assays and in vivo using mouse tumor models.
    Type: Grant
    Filed: March 16, 2010
    Date of Patent: June 25, 2013
    Assignee: Cephalon Australia Pty. Ltd.
    Inventors: Adam W. Clarke, Anthony G. Doyle, Philip A. Jennings, Norbert Kienzle, Matthew Pollard
  • HUMANISED ANTIBODIES WITH ANTI-TUMOUR ACTIVITY
    Publication number: 20100297134
    Abstract: The present invention provides humanised antibodies and binding domains thereof with anti-tumour activity. In particular the humanised antibodies have specific binding to and direct killing of human colon tumour cells and display potent immune-mediated cytotoxic activity against human colon cancer cells in vitro using antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) assays and in vivo using mouse tumour models.
    Type: Application
    Filed: March 16, 2010
    Publication date: November 25, 2010
    Applicant: CEPHALON AUSTRALIA PTY LTD
    Inventors: Adam W. Clarke, Anthony G. Doyle, Philip A. Jennings, Norbert Kienzle, Matthew Pollard